Boston Scientific (BSX) Stock News

Boston Scientific cuts annual outlook again, expects Q4 sales decline.

Boston Scientific shares fall 5.8%, underperform peers on heavy volume.

JP Morgan cut Boston Scientific (BSX) to Neutral from Overweight with a $46 price target, citing valuation and risk-reward balance.

Boston Scientific reported Q3 net sales of $5.138B, up 1.5%, and adjusted EPS of $0.73, down from $0.75 a year ago. The company guided full-year 2026 organic sales growth of about 3.75% and adjusted EPS of $3.16-$3.18, reflecting a challenging year including a cybersecurity incident.

Barclays initiated coverage of Boston Scientific (BSX) with an Equal Weight rating and a price target of $48.

Barclays started coverage of Boston Scientific with an Equal-Weight rating, implying a neutral view. No price target was given.

Boston Scientific appointed Joseph M. Fitzgerald as COO effective Jan. 1, 2027, and will reorganize into three reportable segments: Interventional Therapies, Rhythm Solutions and MedSurg.

The US FDA said Boston Scientific will discontinue the Imager II Angiographic Catheter product line. No reason was given in the initial announcement.

Boston Scientific EVP Arthur C. Butcher will retire as group president of MedSurg and Asia Pacific effective Jan 1, 2027. He will stay as senior advisor through Feb 26, 2027, at his current $780,000 base salary. A retirement agreement with standard benefits is expected.

Boston Scientific expects a material impact on its third-quarter and full-year results. The company said it expects to recover some of the impacted revenue.

The FDA: it is aware that Boston Scientific issued a letter to affected customers recommending that unused Infinion CX leads be removed from where they are used or sold, adding.